Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Abeona Therapeutics (NQ: ABEO ) 7.930 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Apr 17, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Abeona Therapeutics < Previous 1 2 Next > Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) April 01, 2024 From Abeona Therapeutics Inc. Via GlobeNewswire Abeona Therapeutics Reports Full Year 2023 Financial Results and Announces Completion of FDA Inspections March 18, 2024 - FDA completed Pre-License Inspection of Abeona’s Cleveland manufacturing facility, as well as inspection of clinical trial sites for pz-cel pivotal Phase 3 VIITAL™ study - From Abeona Therapeutics Inc. Via GlobeNewswire Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) March 05, 2024 From Abeona Therapeutics Inc. Via GlobeNewswire Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) February 01, 2024 From Abeona Therapeutics Inc. Via GlobeNewswire Abeona Therapeutics Announces Progress Update on Pz-cel Biologics License Application (BLA) February 01, 2024 From Abeona Therapeutics Inc. Via GlobeNewswire Abeona Therapeutics Announces $50 Million Credit Facility January 08, 2024 From Abeona Therapeutics Inc. Via GlobeNewswire Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) December 15, 2023 From Abeona Therapeutics Inc. Via GlobeNewswire Abeona Therapeutics Announces FDA Accepts and Grants Priority Review for Pz-cel Biologics License Application (BLA) November 27, 2023 From Abeona Therapeutics Inc. Via GlobeNewswire Abeona Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Developments November 13, 2023 From Abeona Therapeutics Inc. Via GlobeNewswire Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) November 01, 2023 From Abeona Therapeutics Inc. Via GlobeNewswire Abeona Therapeutics Submits Biologics License Application to U.S. FDA Seeking Priority Review and Approval of EB-101 for the Treatment of Patients with Recessive Dystrophic Epidermolysis Bullosa September 26, 2023 From Abeona Therapeutics Inc. Via GlobeNewswire Abeona Therapeutics Appoints Madhav Vasanthavada, Ph.D., M.B.A. as Chief Commercial Officer September 12, 2023 From Abeona Therapeutics Inc. Via GlobeNewswire Abeona Therapeutics Announces Participation in Upcoming Investor Conferences September 07, 2023 From Abeona Therapeutics Inc. Via GlobeNewswire Abeona Therapeutics Announces Positive Pre-BLA Meeting with FDA for EB-101 and Plans for BLA Submission August 30, 2023 From Abeona Therapeutics Inc. Via GlobeNewswire Abeona Therapeutics Reports Second Quarter 2023 Financial Results August 08, 2023 From Abeona Therapeutics Inc. Via GlobeNewswire Abeona Therapeutics Announces Submission of Briefing Package for Pre-Biologics License Application (BLA) Meeting with FDA in August 2023 July 28, 2023 From Abeona Therapeutics Inc. Via GlobeNewswire Abeona Therapeutics Joins Rare Disease Company Coalition July 19, 2023 From Abeona Therapeutics Inc. Via GlobeNewswire Abeona Therapeutics Announces Closing of $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules July 07, 2023 From Abeona Therapeutics Inc. Via GlobeNewswire Abeona Therapeutics Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules July 03, 2023 From Abeona Therapeutics Inc. Via GlobeNewswire Abeona Therapeutics Announces Regulatory Update on Biologics License Application (BLA) for EB-101 June 09, 2023 From Abeona Therapeutics Inc. Via GlobeNewswire Abeona Therapeutics to Present at the Jefferies Healthcare Conference June 01, 2023 From Abeona Therapeutics Inc. Via GlobeNewswire Abeona Therapeutics Announces Date Change for First Quarter 2023 Portfolio Update Conference Call to May 24, 2023 May 22, 2023 From Abeona Therapeutics Inc. Via GlobeNewswire Abeona Therapeutics Announces New Preclinical Data from its AAV Ophthalmology Program at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) May 16, 2023 Animal proof-of-concept for AAV-based gene therapies for Stargardt disease, X-linked retinoschisis and autosomal dominant optic atrophy From Abeona Therapeutics Inc. Via GlobeNewswire Abeona Therapeutics Reports First Quarter 2023 Financial Results May 11, 2023 From Abeona Therapeutics Inc. Via GlobeNewswire Abeona Therapeutics Announces Additional Phase 3 VIITAL™ Study Results for EB-101 Presented at the International Societies for Investigative Dermatology 2023 Meeting May 11, 2023 From Abeona Therapeutics Inc. Via GlobeNewswire Abeona Therapeutics Announces Multiple Abstracts Accepted from its AAV Ophthalmology Program at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) April 10, 2023 From Abeona Therapeutics Inc. Via GlobeNewswire Abeona Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update March 29, 2023 From Abeona Therapeutics Inc. Via GlobeNewswire Abeona Therapeutics Announces New Employee Inducement Grants March 24, 2023 From Abeona Therapeutics Inc. Via GlobeNewswire Abeona Therapeutics Announces Acceptance of Abstract on EB-101 Phase 3 VIITAL™ Study Results for Oral Presentation at International Societies for Investigative Dermatology (ISID) 2023 Meeting March 16, 2023 From Abeona Therapeutics Inc. Via GlobeNewswire Abeona Therapeutics Announces Update on AAV Ophthalmology Program March 14, 2023 From Abeona Therapeutics Inc. Via GlobeNewswire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.